VALIDATION OF A 22-GENE GENOMIC CLASSIFIER IN PATIENTS WITH RECURRENT PROSTATE CANCER

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

In this ancillary analysis of the RTOG 9601 study, the researchers validated a 22-gene genomic classifier panel as a predictive biomarker for distant metastases in men with recurrent prostate cancer after radical prostatectomy. The final cohort included 352 men, 89.2% of whom were white. Genomic classifier scores in the final cohort were found to be associated with low risk in 42% of patients, intermediate in 38%, and high in 20% of patients. Multivariate analysis revealed a significant association between genomic classifier score and distant metastases, prostate cancer–specific mortality, and overall survival.

The findings of this study represent the first validation of a whole transcriptome–based genomic classifier as a predictive biomarker to help guide decision-making in patients with recurrent prostate cancer after radical prostatectomy. Additional studies may be needed to further expand the analyzed cohort to allow greater generalization.

Download here